Upexi (NASDAQ:GRVI – Get Rating) and biote (NASDAQ:BTMD – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.
Analyst Ratings
This is a breakdown of recent ratings for Upexi and biote, as provided by MarketBeat.
Get Upexi alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Upexi | 0 | 0 | 0 | 0 | N/A |
| biote | 0 | 0 | 4 | 0 | 3.00 |
biote has a consensus price target of $10.25, suggesting a potential upside of 174.80%. Given biote's higher probable upside, analysts clearly believe biote is more favorable than Upexi.
Earnings and Valuation
This table compares Upexi and biote's revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Upexi | $24.09 million | 2.02 | $2.98 million | N/A | N/A |
| biote | N/A | N/A | $11.11 million | N/A | N/A |
biote has lower revenue, but higher earnings than Upexi.
Profitability
This table compares Upexi and biote's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Upexi | 8.10% | 12.48% | 10.39% |
| biote | N/A | -20.05% | 5.99% |
Institutional & Insider Ownership
1.8% of Upexi shares are owned by institutional investors. Comparatively, 3.8% of biote shares are owned by institutional investors. 55.0% of Upexi shares are owned by company insiders. Comparatively, 20.0% of biote shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Upexi has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, biote has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.
Summary
Upexi beats biote on 6 of the 10 factors compared between the two stocks.
About Upexi
(Get Rating)
Grove, Inc., through its subsidiaries, engages in developing, producing, marketing, and selling raw materials, white label products, and end consumer products containing the industrial hemp plant extract, cannabidiol. The company serves consumer markets, including the botanical, beauty care, pet care, and functional food sectors. It also operates annual tradeshow related to the CBD industry in the United States. The company was incorporated in 2018 and is headquartered in Henderson, Nevada.
About biote
(Get Rating)
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
Receive News & Ratings for Upexi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upexi and related companies with MarketBeat.com's FREE daily email newsletter.